January 4, 2021

Innova Medical Group expands U.S. production of COVID-19 Rapid Antigen Tests with acquisition of California-based MPS Medical, Inc.

MPS Medical BuildingPasadena, Calif. (January 2, 2021) Innova Medical Group, Inc., the world’s largest manufacturer of rapid antigen test kits and leader in COVID-19 testing solutions, plans to ramp up U.S. production to almost 700-thousand SARS-CoV-2 Antigen Rapid Qualitative Tests per day. This investment in MPS Medical immediately expands Innova’s global footprint and production of nine-million test kits each day. In the 4th Quarter of 2020, Innova delivered more than 220 million COVID-19 test kits to 20 countries, including the United Kingdom, Hungary, Singapore, United Arab Emirates, Myanmar, and the United States.

“The acquisition of California-based MPS Medical is a testament of our commitment to making top-quality products locally for domestic and international markets,” said Daniel Elliott, President and CEO of Innova Medical Group, Inc. “With Innova’s deep expertise in COVID-19 testing and business strategy, MPS Medical will excel as manufacturer of not only our best-in-class antigen test kits but other innovative medical products, post pandemic.”

With global manufacturing and distribution channels in place, rapid antigen tests with 99.68% accuracy, can be quickly scaled up to meet customer demands. Innova Medical Group is under contract to deliver millions of additional test kits worldwide in the 1st Quarter of 2021. Many of these will ship from the MPS Medical production site in Brea, California.

“We are excited to be part of the fast-growing Innova Medical family and to participate directly in helping the people in the U.S. and other countries to better combat the COVID-19 pandemic,” said Barry Kazemi, CEO of MPS Medical, Inc.

As an FDA-registered medical device manufacturer, MPS Medical, Inc. has produced high-quality medical devices for domestic and international customers since 2014. MPS Medical meets ISO 13485 standards, and its particle-controlled Class 7 cleanroom environment is GMP compliant.  Innova recently acquired Biological Laboratory, Inc. a Clinical Laboratory Improvement Amendments (CLIA) certified lab with more than 130 employees who provide COVID-19 testing services in Los Angeles County. 

Innova Medical Group takes a holistic view in how to manage and create success in the battle against COVID-19. Innova offers an integrated solution, based on the Four Pillars of Testing, Implementation, Monitoring, and Engagement. Besides the superior portfolio of diagnostic and screening tests, Innova’s QMC Health ID app captures test results and creates a “health passport” that enables patients and organizations to report their COVID-19 status in a secure and contactless way.  Innova’s proprietary COVIDlytics, powered by real-time data, assist governments and corporations in tailoring testing protocols to help reopen their economies while minimizing COVID-19 transmission spread. 

About MPS Medical, Inc.

MPS Medical, Inc. develops and manufactures medical devices to advance healthcare across multiple areas of care. Its 30-year company history began in 1990 as MPS Acacia. In 2014, MPS Medical began manufacture of MPS Acacia’s market leading neonatal intensive care products and has since expanded into multiple successful divisions. These include infusion therapy, cell therapy manufacturing, sterile compounding, and in-home pharmacy, as well as OEM services. Its custom manufacturing capabilities enable clinical professionals to create new products to meet the specific needs of their patients. MPS Medical, Inc. maintains Class 7 cleanrooms for production in its Brea, California facilities.

About Innova Medical Group, Inc.

Innova Medical Group, Inc. delivers better global health outcomes with its deep expertise in testing and unique offerings in diagnostic medical devices and services that help tackle some of the world’s most challenging healthcare problems. Innova specializes in innovative screening, testing and diagnostics for cancer, heart disease, arterial calcification, stroke, and virus detection focused on infectious disease. In response to the global pandemic, Innova developed an end-to-end ecosystem of rapid diagnostic and screening tests, along with digital reporting and tracing applications to help organizations manage the COVID-19 crisis.

For more information on Innova Medical Group’s COVID-19 ecosystem or to order COVID-19 rapid diagnostic tests, contact info@innovamedgroup.com

Media Inquiries, contact media@innovamedgroup.com

 

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
MPS Medical Building